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Background: Patients with irritable bowel syndrome (IBS) often feel they have some form of dietary
intolerance and frequently try exclusion diets. Tests attempting to predict food sensitivity in IBS have been
disappointing but none has utilised IgG antibodies.
Aims: To assess the therapeutic potential of dietary elimination based on the presence of IgG antibodies to
food.
Patients: A total of 150 outpatients with IBS were randomised to receive, for three months, either a diet
excluding all foods to which they had raised IgG antibodies (enzyme linked immunosorbant assay test) or
a sham diet excluding the same number of foods but not those to which they had antibodies.
Methods: Primary outcome measures were change in IBS symptom severity and global rating scores. Non-
colonic symptomatology, quality of life, and anxiety/depression were secondary outcomes. Intention to
treat analysis was undertaken using a generalised linear model.
Results: After 12 weeks, the true diet resulted in a 10% greater reduction in symptom score than the sham
diet (mean difference 39 (95% confidence intervals (CI) 5–72); p = 0.024) with this value increasing to
26% in fully compliant patients (difference 98 (95% CI 52–144); p,0.001). Global rating also significantly
improved in the true diet group as a whole (p =0.048, NNT=9) and even more in compliant patients
(p = 0.006, NNT=2.5). All other outcomes showed trends favouring the true diet. Relaxing the diet led to a
24% greater deterioration in symptoms in those on the true diet (difference 52 (95% CI 18–88); p = 0.003).
Conclusion: Food elimination based on IgG antibodies may be effective in reducing IBS symptoms and is
worthy of further biomedical research.
I
rritable bowel syndrome (IBS) is a common disorder which
causes abdominal pain, abdominal distension, and bowel
dysfunction, characterised by loose bowels, constipation, or
a fluctuation between these two extremes.1 This condition
significantly impairs quality of life and places a large burden
on health care resources.2 Treatment of IBS is largely based
on the use of antispasmodics, antidepressants, and medica-
tions that modify bowel habit, depending on whether
constipation or diarrhoea is the predominant problem.1 The
notorious inadequacies of current drug therapy lead to much
patient dissatisfaction and a tendency for patients to seek a
variety of alternative remedies, especially of a dietary nature.
IBS is likely to be a multifactorial condition involving a
number of different mechanisms although the prominence of
any particular factor may vary from patient to patient.1 3
However, patients often strongly believe that dietary intoler-
ance significantly contributes to their symptomatology and
some sufferers seem to benefit from eliminating certain foods
from their diet. Detection of food intolerance is often difficult
due to its uncertain aetiology, non-specific symptomatology,
and relative inaccessibility of the affected organ. Thus most
previous studies have relied on the use of exclusion diets,
which are extremely labour intensive and time consuming.4 5
Attempts to ‘‘test’’ for food intolerance in IBS have largely
focused on ‘‘classic’’ food allergy based on the presence of IgE
mediated antibody responses, although it appears that these
‘‘immediate type’’ reactions are probably quite rare in this
condition.6–10 It is therefore possible that adverse reactions to
food in patients with IBS might be due to some other form of
immunological mechanism, rather than dietary allergy. Such
reactions could be mediated by IgG antibodies, which
characteristically give a more delayed response following
exposure to a particular antigen11 and have been implicated
in some cases of food hypersensitivity.12–14 However, this
mechanism is controversial and is considered by some to be
physiological15–17 especially as IgG food antibodies can be
present in apparently healthy individuals.18–20 It has pre-
viously been suggested that IgG food antibodies may have a
role in IBS21 and it was therefore the purpose of this study to
formally evaluate, in a randomised controlled trial, the
therapeutic potential of an elimination diet based on the
presence of IgG antibodies to food in patients with IBS.
PATIENTS AND METHODS
Patients
All patients with uncomplicated IBS (all bowel habit
subtypes) attending the Gastroenterology Department at
the University Hospital of South Manchester were considered
eligible for the study, and those aged between 18 and
75 years, who satisfied the Rome II criteria,22 were invited to
participate. Tertiary care patients were excluded from the
study. All patients had normal haematology, biochemistry,
and endoscopic examination when indicated. Coeliac disease
was excluded using the tissue transglutaminase test and a
hydrogen breath test was used for excluding lactose intoler-
ance. Patients were also excluded from participating in the
study if they had any significant coexisting disease or a
history of gastrointestinal surgery, excluding appendicect-
omy, cholecystectomy, and hiatus hernia repair. The study
was approved by the local ethics committee and all patients
provided written informed consent.
Methods
The study used a double blind, randomised, controlled,
parallel design in which patients were randomised to either a
‘‘true’’ diet or a ‘‘sham’’ diet control group. At screening,
Abbreviations: IBS, irritable bowel syndrome; ELISA, enzyme linked
immunosorbant assay; AU, arbitrary unit; HAD, hospital anxiety and
depression scale; QOL, quality of life; NNT, number needed to treat
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blood was taken and sent, with only a numerical identifier, to
YorkTest Laboratories Ltd (York, UK) where an enzyme
linked immunosorbant assay (ELISA) test was performed to
detect the presence of IgG antibodies specific to a panel of 29
different food antigens. This test has been described in detail
elsewhere23 and involves specimens being diluted 1/50, 1/150,
and 1/450 with each dilution applied to an allergen panel.
Each test was calibrated using 0 arbitrary unit (AU) and
25 AU standards prepared from a serum with a high IgG titre
to a cow’s milk allergen extract. A positive control serum at
45 AU was applied to each test. The test results were obtained
from the 1/150 dilution of the specimen. Where a high
specimen background was observed, the test results were
obtained from the 1/450 dilution. The threshold for a positive
(reactive) result was selected as three times the background
signal obtained by the same sample against a no food
allergen coated control well equivalent to 3 AU. Test results
were scored as positive or negative only, relative to this cut
off.
Staff based at the YorkTest Laboratories produced a true
and sham diet sheet for each patient. The sham diet
eliminated the same number of foods to which a patient
exhibited IgG antibodies but not those particular foods. The
goal was to try and include in the sham diet an equally
difficult to eliminate staple food for every staple food in the
true diet. Thus cow’s milk was (generally) replaced with
potato, wheat with rice, and yeast with whole egg, where this
was possible. Nut reactivities were replaced with other nuts
in the sham diet, and legumes with other legumes, but this
was not systematised.
The true and sham diet sheets for each patient were sent to
the University of York, again with only a number for
identification. Patients were allocated to one of the two diet
sheets based on a randomisation schedule developed using a
random computer number generator. Thus patients would
receive either an elimination diet based on their true
sensitivity results (true diet) or a sham diet. All patients
and clinical staff in the Gastroenterology Research
Department and YorkTest Laboratory were blinded to the
group assignment of all patients for the duration of the study.
Patients were given their allocated diet sheet by staff at the
Gastroenterology Research Department and asked to elim-
inate the indicated foods from their diet for a period of
12 weeks. They also received a booklet with advice on
eliminating the different foods and the telephone contact
details of a free nutritional advisor whom they were able to
contact for further advice if necessary.
Symptoms were assessed using a questionnaire scoring
system validated for use in IBS, including the IBS symptom
severity score (range 0–500).24 This is a system for scoring
pain, distension, bowel dysfunction, and general well being,
with mild, moderate, and severe cases indicated by scores of
75–175, 175–300, and .300, respectively. A reduction in
score of 50 or over is regarded as a clinically significant
improvement.24 Non-colonic symptomatology,25 such as
lethargy, backache, nausea, and urinary symptoms, was
assessed and scored using visual analogue scales (range 0–
500). Quality of life (QOL) was measured using an instru-
ment proven to be sensitive to change in IBS (range 0–500).26–28
Anxiety and depression were evaluated using the hospital
anxiety and depression scale (HAD).29 This instrument scores
anxiety and depression up to a maximum score of 21 for each
parameter, with a score above 9 indicating significant
psychopathology. Data on these measures were recorded at
baseline and after 4, 8, and 12 weeks of the dietary
intervention period. In addition, at 4, 8, and 12 weeks,
patients were asked to give a global rating of their IBS using
the question, ‘‘Compared with your IBS before you started
the food elimination diet, are you now: terrible, worse,
slightly worse, no change, slightly better, better, or excel-
lent?’’ The atopic status of all patients entering the study was
also assessed.
During the treatment phase, patients were allowed to take
concomitant medication provided it had been constant for six
months prior to the start of the study. They were encouraged
not to alter medication use during the course of the trial but
any changes were recorded. Any patient withdrawing from
the study was encouraged to complete a final symptom
questionnaire at week 12 and their reasons for withdrawal
were recorded. At the end of 12 weeks, patients were asked to
resume consumption of the foods they had been advised to
eliminate in order to assess the effect of their reintroduction.
Patients were then reassessed after four weeks using the
same measures and the result compared with their scores at
the end of the elimination phase.
Data analysis
Questionnaires were scored by an assessor blinded to the
randomisation. The primary outcome measures were changes
in IBS symptom severity score and global impact score at
12 weeks. Changes in non-colonic symptoms, QOL, and HAD
scores were regarded as secondary outcome measures. Two
sample t tests were used to establish whether there was an
overall difference in the change in continuous outcome
measures between the two groups of patients. Patients were
analysed according to the group to which they were
randomised, independent of their adherence to the diet.
The global impact score, an ordered categorical variable, was
analysed using a Wilcoxon Mann-Whitney test to compare
the numbers in the active and sham groups showing
significant improvement (‘‘better’’ or ‘‘excellent’’), no sig-
nificant change (‘‘slightly worse’’, ‘‘no change’’, or ‘‘slightly
better’’), and significant deterioration (‘‘worse’’ or ‘‘terri-
ble’’). The number needed to treat (NNT) was calculated
from the global impact score by calculating the reciprocal of
the difference in probability of a significant improvement
between the treatment and control groups. General linear
modelling in SPSS was used to explore whether there was a
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Figure 1 Study flow diagram.
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relationship between the change in symptoms from baseline
and treatment group, patient characteristics (for example,
IBS subtype, history of atopy, number of foods to which
sensitive, and concomitant medication) and adherence to the
diet.30
Sample size calculation
It was estimated that approximately 40% of the placebo arm
would report a significant improvement in symptoms. It was
calculated that a sample size of 55 patients would be required
in each group to detect, with 90% power, a difference of 30%
points in the proportion reporting such an improvement (that
is, 70% in the treatment arm) as statistically significant at the
5% level. Assuming a 20% dropout rate, a minimum of 138
patients would need to be entered into the trial. Thus we
aimed to recruit a total of 150 patients into the study.
RESULTS
Recruitment of patients and their flow through each stage of
the study is illustrated in fig 1, as recommended by the
CONSORT statement.31 In summary, between January 2001
and July 2002, 176 patients were eligible for the study, of
which 26 (15%) were excluded from participation, leaving
150 patients who were all found to be sensitive to at least one
food. Seventy five of these were randomised to receive an
elimination diet based on their true food sensitivity results
and 75 patients to a sham diet. Data from 131 (87%) patients
who gave 12 week data were available for the intention to
treat analysis: 65 and 66 patients from the true and sham
groups, respectively.
Patient characteristics
The patients were typical of those with IBS in secondary care
practice, the majority being women. Patients, on average, had
experienced symptoms of IBS for over a decade and were
found to be sensitive to approximately 6–7 foods (range 1–
19). Baseline demographic and clinical characteristics of the
two groups, including the use of concomitant medication,
were found to be similar with the exception of the IBS
symptom severity score which was slightly higher in the
treatment group (table 1). Thirty per cent of patients were
found to be atopic.
The frequency of foods excluded from the diet is shown in
table 2. Adherence was lower in those on the true diet
although no specific adverse events were recorded in either
group. Twenty four patients withdrew from the study in the
true diet group (mainly because of difficulty in following the
diet) and 13 from the sham diet group (for a variety of
reasons). However, 12 week data were obtained from 14 of
those who withdrew in the true diet group and four in the
sham diet group. There were no significant differences
Table 1 Baseline characteristics of the patients
Group True diet (n = 75) Sham diet (n = 75)
Age (y) (range, SD) 44 (17–72; 12.9) 44 (19–74; 15.2)
No of males (%) 7 (9.3%) 13 (17.3%)
No of foods to which sensitive 6.65 (3.66) 6.63 (4.1)
Symptom duration (y) 11.5 (9.9) 10.1 (7.5)
IBS symptom severity score 331.9 (70.8) 309.0 (78.5)
Non-colonic features score 459.1 (160.7) 452.6 (170.1)
Quality of life score 640.1 (252.6) 639.3 (222.3)
HAD anxiety score 9.5 (4.6) 9.5 (4.5)
HAD depression score 5.3 (3.4) 6.0 (3.6)
No of diarrhoea predominant patients (%) 37 (52.1%) 41 (56.9%)
No of constipation predominant patients (%) 19 (26.8%) 16 (22.2%)
No of alternating predominant patients (%) 15 (21.1%) 15 (20.8%)
Results are expressed as mean (SD).
HAD, hospital anxiety and depression scale.
Table 2 Frequency of foods excluded from the diet (% of
patients)
Food Treatment group Sham group
Barley 26.7 9.3
Corn 22.7 14.7
Rice 8 54.7
Rye 8 25.3
Wheat 49.3 8
Milk 84.3 1.3
Beef 24 9.3
Chicken 21.3 13.3
Pork 5.3 36
Cabbage 12 24
Celery 5.3 21.3
Haricot bean 17.3 14.7
Pea 38.6 1.3
Potato 9.3 61.3
Soy bean 22.7 10.7
Tomato 4 44
Apple 1.3 33
Orange 6.7 29.3
Strawberry 0 20
Almond 28 12
Brazil nut 22.7 17.3
Cashew nut 49.3 8
Peanut 10.7 20
Walnut 2.7 29.3
Cocoa bean 1.3 21.3
Shellfish 21.3 10.7
Fish mix 17.3 28
Whole egg 57.3 26.7
Yeast 86.7 0
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Figure 2 Mean change in symptom severity scores at 12 weeks
according to degree of adherence. Difference between the groups with
high adherence: 101 (95% confidence interval 54, 147); ***p,0.001.
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between baseline characteristics of the 19 who were lost to
follow up and those for whom 12 week data were obtained.
Primary outcomes
IBS symptom severity
Patients in the true diet group experienced a 10% greater
reduction in symptom severity than those allocated to the
sham diet, with change in scores of 100 and 61.5, respectively
(mean difference 39 (95% confidence interval (CI) 5.2, 72.3);
p=0.024): a standardised effect size of 0.52 (see fig 3A).
There were no differences in the response to the diet in terms
of age, sex, IBS bowel habit subtype, or IBS duration. In
addition, there was no difference in response to the diet
between atopic and non-atopic patients. There was however a
statistically significant interaction between treatment group
and both adherence to the diet and number of foods to which
patients were sensitive. For patients sensitive to the average
number of foods who fully adhered to their allocated diet, a
26% difference in reduction in symptom severity score was
observed in favour of the true diet (a difference in score of 98
(95% CI 52, 144), p,0.001: a standardised effect size of 1.3).
This benefit increased by a further 39 points (12%) (95% CI 7,
70; p= 0.016) for each food to which they were sensitive
over and above the average number. These results were not
materially altered by carrying out an ANCOVA analysis (in
which the final score is the dependent variable and the
baseline score is included as a covariate) instead of modelling
change in scores.30 The interaction between treatment group
and adherence is demonstrated in fig 2 which shows a
greater reduction in symptoms with full adherence in the
true diet but not in the sham diet group. Figure 3A and 3B
show the average change in symptom severity score over
12 weeks for the group as a whole and for those who fully
adhered, respectively. This reveals that most improvements in
symptoms are fully achieved within two months.
Global impact score
The reported global rating of change by treatment group is
shown in table 3. The difference in mean ranking (70.9 v
60.3) was statistically significant (p=0.048). When this was
repeated including only patients who fully adhered to their
diets (table 3), a greater percentage difference favouring the
true diet was found (p=0.001). The NNT was 9 in the group
as a whole and 2.5 in patients fully adherent to the diet.
Secondary outcome measures
As can be seen from fig 4A and 4B, all data show changes
favouring the true diet group and are consistent with the
results for the primary outcomes. These trends were further
strengthened after adjustment for adherence and number of
food sensitivities but only reached statistical significance for
non-colonic symptomatology (p=0.05). There were no
significant changes in medication use during the course of
the trial.
Reintroduction of eliminated foods
Of the 131 patients who gave 12 week data, 93 (41 in the true
and 52 in the sham diet groups) agreed to attempt
reintroduction of foods they had been asked to eliminate
and provided further follow up data on the primary outcomes
measures. Of these, 62% reported full adherence and 37%
moderate adherence to the previous elimination diet. Mean
IBS symptom severity score increased (that is, worsening of
symptoms) by 83.3 in the true group and by 31 in the sham
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Figure 3 (A) Average symptom severity scores over time for the group
as a whole. Difference in mean change from baseline at 12 weeks: true
versus sham 39 (95% confidence interval 5, 72); *p=0.024. (B) Average
symptom severity scores over time for the full adherence group.
Difference in mean change from baseline at 12 weeks: true versus sham
98 (95% confidence interval 52, 144); ***p,0.001.
Table 3 Global impact score at 12 weeks
Treatment group
True diet
(n (%))
Sham diet
(n (%))
All patients
Significantly worse 3 (4.7) 8 (12.1)
No significant change 44 (67.2) 47 (71.2)
Significantly improved 18 (28.1) 11 (16.7)
Total 65 66 NNT = 9
Patients fully adhering to the diet
Significantly worse 1 (4.2) 5 (12.5)
No significant change 10 (41.7) 29 (72.5)
Significantly improved 13 (54.1) 6 (15)
Total 24 40 NNT = 2.5
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group, a statistically significant difference of 52 (24%) (95%
CI 18, 86; p=0.003). The change in global score following
reintroduction of foods is shown in table 4. This indicates a
reversal of the pattern observed during the active treatment
phase, with more patients in the true diet group showing
worsening of health compared with the sham diet group
(p=0.047).
DISCUSSION
A clinically significant improvement in IBS symptomatology
was observed in patients eliminating foods to which they
were found to exhibit sensitivity, as identified by an ELISA
test for the presence of IgG antibodies to these foods. The
number needed to treat of 9 for the group as a whole and 2.5
for patients closely adhering to the diet are both considerably
better than the value of 17 achieved after three months of
treatment with tegaserod,32 a drug that has been recently
licensed in the USA for use in IBS. IBS symptom severity and
global rating scores were chosen as primary outcome
measures in this study as they represented the most direct
measure of clinical improvement in this condition based on
patient self assessment. Rather than using the traditional
method of classifying global improvement as any value
exceeding adequate relief of symptoms, we used a much
stricter definition requiring patients to report symptoms as
being either ‘‘better’’ or ‘‘excellent’’ compared with pretreat-
ment levels. Despite this, the diet still achieved a significant
improvement. However, as might be expected, the placebo
response using this end point was somewhat lower than that
usually reported in IBS treatment trials which have used less
demanding criteria. The observation that patients on the
sham diet also improved, although to a lesser extent,
emphasises the importance of conducting double blind
randomised controlled trials of such non-drug interventions
in order to avoid overestimating their potential.
Most patients with IBS have attempted at least some form
of dietary modification, which in some cases can be very
extreme. Conflicting results have been reported using
exclusion diets4 5 33–36 and this approach also suffers from
the limitation that it has to be empirical. Thus potentially
offending foods can only be identified after their elimination
and subsequent reintroduction. This time consuming process
would be much reduced if the offending foods could be
identified beforehand. Attempts to do this using IgE
antibodies have been disappointing8–10 but the results of this
study suggest that measuring IgG antibodies may be much
more rewarding. The response to the IgG based diet in our
trial did not correlate with atopic status, the prevalence of
which was found to be no greater than that occurring in the
general population.37
The observation that adherence to the diet is critical in
determining a good outcome in the ‘‘true’’ diet group but not
the ‘‘sham’’ group is indicative of the fact that the diet is an
‘‘active treatment’’ which if not adhered to, does not seem to
have an effect. This notion is further supported by the
observation that a significantly greater deterioration was
observed in subjects in the true diet group compared with
those in the sham group when they reintroduced eliminated
foods at the end of the diet phase of the trial. Furthermore,
the improvement of 98 in the symptom severity score in those
fully adherent in the true diet group is well above the value of
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Figure 4 (A) Mean change in the secondary outcome measures of non-
colonic symptoms and quality of life for the group as a whole and the full
adherence group. (B) Mean change in the secondary outcome measures
of anxiety and depression for the group as a whole and the full
adherence group.
Table 4 Global rating following reintroduction of foods
relative to the end of the elimination phase
Treatment group
True diet group
(n (%))
Sham diet group
(n (%))
Significantly worse 17 (41.5) 13 (25)
No significant change 23 (56.1) 35 (67.3)
Significantly improved 1 (2.4) 4 (7.7)
Total 41 (100) 52 (100)
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50, which is regarded as being of clinical significance both in
validation studies24 and clinical practice.26–28 It was interesting
to note that patients exhibiting a greater number of
sensitivities, as determined by the IgG test, experienced a
greater symptom reduction if they adhered to the true but not
the sham diet.
There is currently considerable interest in the concept that
at least in some patients, IBS may have an inflammatory
component.38–42 Most of the work in this area has centred on
post dysenteric IBS, with gut pathogens being viewed as the
initiators of this process which can be identified by subtle
changes on histology.38 However, if, as indicated in this study,
IgG antibodies to food are important in the pathogenesis of
IBS in some patients, they too may be of relevance. Not all
patients exhibiting histological features consistent with post
dysenteric IBS give a history of a previous dysenteric illness.
This is usually assumed to be due to the fact that this has
been forgotten by the patient but our results may suggest an
alternative mechanism for immune activation and inflam-
mation without the need for prior infection.
It is now well recognised that up to 70% of patients with
IBS have evidence of hypersensitivity of the rectum,43 which
probably extends to involve most of the gut in many
individuals.44 It is possible that this hypersensitivity renders
patients more reactive to a low grade inflammatory process
which would not necessarily cause symptoms in a normal
individual. This would explain why excluding foods to which
patients have IgG antibodies might be particularly beneficial
in IBS despite the fact that these antibodies may also be
present in the general population. Indeed, if this mechanism
is particularly important in IBS, it might be anticipated that
IgG food antibodies would be relatively common in this
condition, as was the case in our study.
Many patients with IBS would prefer a dietary solution to
their problem rather than having to take medication, and the
economic benefits of this approach to health services are
obvious. It is well known that patients expend large sums of
money on a variety of unsubstantiated tests in a vain attempt
to identify dietary intolerances. The results of this study
suggest that assay of IgG antibodies to food may have a role
in helping patients identify candidate foods for elimination
and is an approach that is worthy of further biomedical and
clinical research.
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